Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg hypertension and diabetes project

Journal of Hypertension

Volumn 21, Issue 9, 2003, Pages 1657-1662

  Östgren, Carl J ^a,b   Lindblad, UIf ^a,c   Melander, Olle ^a   Melander, Arne ^a,d   Groop, Leif ^a   Råstam, Lennart ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Odeshog Health Care Centre   (Sweden)

^c Skaraborgs Institutet   (Sweden)

^d Network for Pharmacoepidemiology Foundation   (Sweden)

Author keywords

Association study; Blood pressure; Diabetes mellitus; Genetics; Hypertension; Peroxisorne proliferator activated receptor ; Polyrnorphism; Primary care; Pro12Ala

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PRO12ALA GENE; RISK ASSESSMENT; RISK FACTOR;

EID: 0042733635     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200309000-00014     Document Type: Article

References (19)

1. Willson T, Brown P, Sternbach D, Henke B. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550.
2. Spencer C, Markham A. Troglitazone. Drugs 1997; 54:89-101.
3. Ghazzi M, Perez J, Antonucci T, Driscoll J, Huang S, Faja B. The Troglitazone Study Group, Whitcomb RW. Cardiac and glycemic benefits of Troglitazone treatment in NIDDM. Diabetes 1997; 46:433-439.
4. Altshuler D, Hirschhorn J, Klannemark M, Lindgren C, Vohl MC, Nemesh J, et al. The common PPARγ. Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
5. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitition in PPAR γ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 3:284-287.
6. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271:212-216.
7. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, et al. Pro12Aia substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999; 48:1466-1468.
8. Swarbrick M, Chapman ML, McQuillan B, Hung J, Thompson P, Beilby J. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-γ2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001; 144:277-282.
9. Hasstedt SJ, Ren OF, Teng K, Elbein SC. Effect on the peroxisome proliferator-activated receptor gamma pro12ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001; 86:536-541.
10. Douglas J, Erdos M, Watanabe R, Braun A, Johnston C, Oeth P, et al. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant. Association with type 2 diabetes and trait differences. Diabetes 2001; 50:886-890.
11. World Health Organization Expert Committee. Diabetes mellitus. Technical Report Series, No. 742. Geneva: World Health Organization; 1985.
12. Bøg-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L. Risk factor clustering in patients with hypertension and NIDDM. J Int Med 1998; 243:223-232.
13. Östgren CJ, Lindblad U, Bøg-Hansen E, Ranstam J, Melander A, Råstam L. Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes. Diabetes Obesity Metab 1999; 1:105-112.
14. National Board of Health and Welfare, Drug Information Committee. Treatment of Mild Hypertension. Stockholm: National Board of Health and Welfare; 1987.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
16. Haffner S, Miettinen H, Stern M. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20:1087-1092.
17. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268:178-182.
18. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, et al. Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptors in vascular smooth muscle cells. Circulation 2000; 102:1834-1839.
19. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, et al. Transcriptional supression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ2 in vascular smooth muscle cells. Endocrinology 2001; 142:3125-3134.